HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Online supplement All Versions of this Article: 32/1/180    most recent 09031936.00129907v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, M. C. Articles by Teeter, J. G. Search for Related Content PubMed PubMed Citation Articles by Liu, M. C. Articles by Teeter, J. G.

Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes

¹ Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, ² Pfizer Global Research and Development, New London, CT, ³ Division of Pulmonary and Critical Care Medicine, University of California San Francisco at Fresno, and ⁴ Valley Research, Fresno, CA, USA.

CORRESPONDENCE: M. C. Liu, Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. Fax: 1 4105502612. E-mail: mcl{at}jhmi.edu

Keywords: Bronchoalveolar lavage, bronchoscopy, Exubera®, glycaemic control, pulmonary function tests

Received: October 2, 2007
Accepted February 4, 2008

Inhaled human insulin (Exubera® (human insulin of rDNA origin) Inhalation Powder) causes small, early and reversible changes in pulmonary function in subjects with diabetes mellitus. The present study assessed whether changes occur in cellular and soluble constituents of airway lining fluid consistent with inflammation as a possible cause for Exubera®-associated lung function alterations.

Two 31-week, open-label, sequential design phase 2 studies were conducted, one with 20 subjects with type 1 and one with 24 subjects with type 2 diabetes. After run-in, all subjects received subcutaneous insulin for 12 weeks, followed after 1 week by 12 weeks of Exubera®. Bronchoalveolar lavage fluid cell counts and protein constituents were determined at baseline, after 12 weeks of subcutaneous insulin and after 12 weeks of Exubera®.

Baseline cellular and soluble constituents of lavage fluid were similar to those reported for nondiabetic adults. Exubera® produced no consistent clinically or statistically significant changes in total or differential lavage fluid cell counts or protein concentrations, even though Exubera®-associated changes in pulmonary function are known to be fully manifest within 12 weeks.

Therefore, 12 weeks of Exubera® treatment is not associated with evidence of pulmonary inflammation. The treatment effects on lung function observed in Exubera® trials are not caused by lung inflammation.

This article has been cited by other articles:

				M. Papagianni, A. Hatziefthimiou, G. Chachami, K. Gourgoulianis, P-A. Molyvdas, and E. Paraskeva Inhaled insulin does not trigger lung inflammation and airway remodelling Eur. Respir. J., February 1, 2009; 33(2): 444 - 445. [Full Text] [PDF]